AAV Transduction Efficiency in Human iPSC-Derived Cardiomyocytes

This poster presents a human-based screening platform developed by Ncardia to evaluate the transduction efficiency, cytotoxicity, and overall performance of multiple AAV serotypes in hiPSC-derived cardiomyocytes, supporting more informed vector selection for gene therapy applications. 

Download it now for a closer look at:

• How different AAV serotypes perform in human iPSC-derived cardiomyocytes across a range of multiplicities of infection, highlighting clear differences in transduction efficiency and viability profiles 
  
• How fluorescence intensity and GFP expression evolve over time, providing insight into vector performance and stability post-transduction
• The relationship between increasing MOI and both transduction efficiency and cytotoxicity, supporting more balanced decision-making in vector selection 
• How a standardized, high-content imaging platform enables reproducible comparison of AAV candidates in a human-relevant cardiac model 

• Quantitative data showing that AAV1 and AAV5 achieve the highest transduction efficiencies, while AAV4 shows no measurable transduction in this system